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Abstract 
Molecular biomarkers are commonly used for the management of several types of malignant tu-
mours in routine clinical practice. However, this is not the case for malignant gliomas. Cytokines 
and Angiogenesis factors are potential candidates due to their intrinsic role in tumourigenesis. 
Pre- and post-operative serum from 36 malignant glioma patients and 36 controls was analysed 
using the Bio-Plex Pro Angiogenesis and Cytokines Assay (Bio-Rad, USA). Amongst the molecules 
tested, the serum concentration of follistatin was significantly higher in patients than in controls. 
Moreover, the serum concentration of follistatin of the patients postoperatively was significantly 
reduced compared to that preoperatively. Factors such as age and gender did not affect the con-
centrations of follistatin measured in the serum of patients pre- and post-operatively as well as 
healthy controls. This is the first report of follistatin as potential biomarker for the detection of 
malignant gliomas. 
 
Keywords 
Serum, Malignant Gliomas, Follistatin, Biomarker, Cancer 
 
 
1. Introduction 
A biomarker is a measurable substance, which can be used to indicate a biological state. Such state can be a 
normal biological process, a disease or even a pharmacological response to treatment. Examples of commonly 
used biomarkers include Glycated Haemoglobin (Hb1Ac) for diabetes mellitus, blood pressure monitoring in 
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hypertension, and chromosomal abnormalities in genetic syndromes [1].  
Biomarkers are also widely used in the overall management of malignant tumours [2]. They are important 
aids, as they allow prognostication, early detection of recurrence and monitoring during treatment [2]. They are 
already used as part of disease monitoring in several common cancers, such as prostate cancer and ovarian can-
cer, hepatocellular cancer, to name a few [3]-[5]. 
Gliomas derive from glial cells.These can be ependymomas, deriving from ependymal cells, astrocytomas 
from astrocytes, oligodendrogliomas from oligodendrocytes and mixed gliomas such as oligoastrocytomas from 
different types of glial cells. The most common grading system for gliomas is the World Health Organisation 
(WHO) grading system which classifies gliomas in low grade gliomas (WHO grade I and II) and high grade 
ones (WHO grade III and IV). This classification takes into account pathological characteristics for each grade. 
The histopathological hallmarks of high grade gliomas include mitotic activity, cellular pleomorphism, necrosis 
and microvascular proliferation [6].  
The aetiology of malignant gliomas is unknown. They are rarely related to radiation exposure. They can occur 
sporadically or as part of hereditary syndromes (Li-Fraumeni, NF1 and Turcot). Recent studies of molecular 
genetics have suggested that glioblastomas may arise by two separate pathways, primary or de novo glioblasto-
ma and secondary glioblastoma. Secondary glioblastomas arise by malignant progression from a low grade gli-
oma whereas de novo glioblastomas arise without a lower grade precursor. The two subtypes of glioblastoma are 
characterized by different genetic alterations. The de novo glioblastomas frequently have Epidermal Growth 
Factor Receptor gene amplification (EGFR), overexpression of Mouse Double Minute 2 (MDM2) and Phospha-
tase and tensin homolog deleted on chromosome 10 (PTEN) mutations whilst the secondary tumours show p53 
gene mutations and PDGFR-α (platelet-derived growth factor receptor-α) overexpression. Glioblastoma multi-
forme (WHO IV) is the commonest malignant glioma [7] [8].  
The clinical presentation of malignant gliomas depends on the site of their origin. They generally cause focal 
neurological signs, signs of raised intracranial pressure such as headaches, nausea and vomiting as well as 
seizures.  
Malignant gliomas can occur at any age but most commonly after the age of 40. Their peak incidence is be-
tween 65 and 75 years of age [9] [10].  
The overall management of malignant gliomas is particularly challenging [11]. They are difficult to diagnose 
at an early stage as they may not reveal their presence until they have reached a considerable size or have in-
vaded vital areas of the brain. These factors limit the extent of radical treatment that can be offered to the pa-
tients affected by these tumours [12]. Brain tumour biomarkers would aid early diagnosis as well as enable cli-
nicians to offer more radical treatment which would lead to better outcomes [12]. 
In recent years, several studies have identified potential candidate molecules as brain tumour biomarkers but 
so far very few of them have been used in clinical practice [13]. Amongst the most promising ones for clinical 
use are the Cytokines and the Angiogenesis factors. Some of these molecules such as vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF) are obvious candidate serum biomarkers for 
malignant gliomas as they are directly involved in tumour angiogenesis [14]. Less obvious ones are those play-
ing a more peripheral role in tumour proliferation. An example of such a potential biomarker is the glycoprotein 
follistatin (FLT). 
Follistatin is expressed in nearly all tissues [15]-[18]. Its main function is to bind and neutralise Transforming 
Growth Factor (TGF) [15]-[18]. It has been reported that follistatin suppresses tumour invasion in several ma-
lignancies including lung, ovarian and endometrial cancer, as well as oral squamous carcinoma [15]-[18]. Sa-
kamoto and co-workers report that subjects with chronic kidney disease, chronic liver disease, advanced solid 
cancer as well as haematological malignancies have higher concentrations of FLT than apparently healthy indi-
viduals [19]. Several studies report the “normal range” of follistatin, but its concentration varies with different 
assays used as well as the type of sample (serum vs. plasma) used to make the measurement [20]-[23]. 
Here we investigate whether an increase in serum follistatin concentration is correlated with the presence of 
malignant gliomas. Furthermore, we examine the effect of parameters such as the presence of brain tumour, the 
operative stage, the age and the gender, to the serum concentration of this angiogenesis factor. 
2. Materials and Methods 
2.1. Ethical Approval 
A protocol for obtaining serum and plasma samples from patients and healthy controls, along with background 
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information for the project to be undertaken and consent forms for patients, healthy controls and next of kin 
were drawn up and submitted to the Cambridgeshire 3 Research Ethics Committee at the National Research 
Ethics Service, for ethical approval. Ethical permission was duly obtained (REC reference number 09/H0306/ 
50). 
2.2. Patient Recruitment 
Serum samples were collected from 36 glioma patients and 36 controls immediately pre-operatively and within 
24 hours after undergoing operation. All glioma patients were diagnosed with Glioblastoma Multiforme. Control 
patients were defined as patients treated surgically under a general anaesthetic in Preston’s Neurosurgical Unit 
for benign disease (i.e. degenerative spinal disease such as disc protrusion or ligamentous thickening), with no 
past medical history including no known malignancy. None of the controls were on regular medications and in 
particular steroids of any form. Unlike the controls, glioma patients were administered Dexamethasone in high 
dose (16 mg/day). The serum concentration of follistatin was measured using a Bio-Plex Pro Angiogenesis and 
Cytokines Assay (Bio-Rad, USA) according to the manufacturer’s instructions [24]. 
2.3. Sample Preparation 
Briefly, serum samples (50 μl per well) or standards (50 μl per well) were incubated with 50 μl of the pre-mixed 
bead sets in pre-wetted 96-well microtiter plates at room temperature for 30 minutes. After washing, 25 μl of the 
fluorescent detection antibody mixture was added for 30 min. After washing, 50 μl of streptavidin-phycoerythrin 
was added to each well and 10 min incubation at room temperature took place. After washing, 125 microliters of 
assay buffer was added to each well. The plate was shaken at 1100 rpm for 30 sec at room temperature prior to 
placing it into a plate reader (excitation at 546 nm, emission at 575 nm). A range of 3.2 - 10,000 pg/mL recom-
binant full-length follistatin protein was used to establish a standard curve. Follistatin concentrations were de-
termined using a Bio-Plex 200 System (Bio-Rad Laboratories INC, USA). The Bio-Plex Manager software 
(Bio-Rad Laboratories INC, USA) was used for data acquisition and analysis. The data are reported as relative 
median fluorescent intensities [25]. 
2.4. Data Analysis 
All performed statistical tests were included in the R Statistical package [26]. Outliers were removed using the 
Fourth-Spread method [27]. Normal distribution of the data was confirmed using a Shapiro-Wilk normality test 
(p-value 0.05) [28] and statistical significance evaluated using a Student’s t-test [29] at a level of α = 0.001.  
3. Results 
3.1. Serum Follistatin Concentration Comparison across All Patients and Controls 
The serum concentration of follistatin was significantly higher in glioma patients (P < 0.001) prior to operation 
(1133 ± 279 pg/ml) than after the operation (86 ± 44 pg/ml) (Figure 1, Boxplot (a)). Similarly, the preoperative 
controls had significantly higher serum concentration of follistatin than the postoperative glioma patients (335 ± 
93) (Figure 1, Boxplot (a)). Furthermore, a significant difference was observed in the preoperative serum con-
centration of follistatin between patients and controls (α = 0.001). 
The significantly higher serum concentration of Follistatin in the preoperative patients and controls compared 
to the postoperative patients, as well as between preoperative patients and preoperative controls was also con-
firmed across all the different age groups tested (i.e. 0 - 39, 40 - 69 and 70 - 100 of years of age) (P < 0.001) 
(Figure 1, Boxplots (b)-(d)).  
3.2. Age Group Comparison within the Pre- and the Post-Operative Datasets 
A pairwise comparison of the serum concentration of follistatin was performed between the three age groups in 
the preoperative, the postoperative and control datasets (i.e. preoperative 0 - 39 vs. preoperative 40 - 69; 
preoperative 0 - 39 vs. preoperative 70 - 100, etc.). This was done in order to investigate whether age plays a 
role on follistatin’s serum concentrations. No significant difference was observed between the different age 
groups for either the controls, or the patients prior to or after their operation (α = 0.001). 
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Figure 1. Boxplots summarizing the preoperative (Pre-Op) and postoperative (Post-Op) serum concentration (pg/ml) of fol-
listatin measured in the malignant glioma patients and controls (Pre-Op Control) across the different age groups 0 - 100 (a), 0 - 
39 (b), 40 - 69 (c), 70 - 100 (d). Asterisks (*) indicate pairwisesignificant difference between datasets (P < 0.001).                    
3.3. Effect of Gender on Serum Concentration of Follistatin Pre- and Post-Operatively 
The effect of gender on the serum concentration of follistatin pre- and post-operatively as well as between the 
tumour patients and the controls was examined. The two gender groups did not exhibit any significant difference 
on the serum concentration (pg/ml) of follistatin (male preoperative: 1145 ± 309 vs. female preoperative: 1114 ± 
237; male postoperative: 76 ± 37 vs. female postoperative: 100 ± 51) (α = 0.001) (Figure 2). Providing that fol- 
listatin is indeed a credible biomarker for glioblastomas, this finding suggests that glioblastomas are not prefe- 
rentially linked to a specific gender. These observations held true regardless of the operative stage (pre- vs. 
post-operative). On the contrary, when the operative stages (pre- vs. post-operative) of glioma patients were com-
pared against each other for each gender separately, both male and female datasets had shown highly significant  
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Figure 2. Boxplots summarizing the serum concentration (pg/ml) of follistatin measured in the male and female malignant 
patients across all ages pre-operatively, post-operatively, as well as the control patients pre-operatively. Asterisks (*) indicate 
pairwisesignificant difference between datasets (P < 0.001). In addition, boxplots of the follistatin serum concentration (pg/ 
ml) between the two genders prior to the operation, postoperatively and in the controls are also shown. None of these com-
parisons resulted in significantly different serum concentrations of follistatin (α = 0.001).                                         
 
differences in their serum concentration (pg/ml) of follistatin (male preoperative: 1145 ± 309 vs. male postope-
ratively: 76 ± 37 and female preoperatively: 1114 ± 237 vs. female postoperatively: 100 ± 51) (P < 0.001) 
(Figure 2). 
Similarly to the results above, gender didn’t seem to have an effect on the serum concentration (pg/ml) of fol-
listatin in the pre-operative controls either (male preoperative control 347.757 ± 97.467 vs. female preopative 
control 314.983 ± 86.841) (α = 0.001) (Figure 2). However, male and female controls had significantly different 
follistatin serum concentrations (pg/ml) when were compared to their equivalent preoperative patient samples 
(male preoperative control 348 ± 97 vs. male preoperative patient: 1145 ± 309; female preoperative control 315 ± 
87 vs. female preoperative patient: 1114 ± 237) (P < 0.001) (Figure 2). 
4. Discussion 
Angiogenesis factors such as the VEGF and PDGF-BB have been previously proposed as potential candidate 
biomarkers to aid the management of malignant gliomas [30]-[35]. In this study follistatin serum concentrations 
have shown a significant correlation with the presence of malignant gliomas. More specifically, the average se-
rum concentrations found in the healthy population (i.e. controls) for follistatin were 335 (±93) pg/ml whereas in 
the population with malignant tumour was 1133 (±279) pg/ml which later dropped down to 86 (±44) pg/ml after 
the operation.  
Interestingly, follistatin serum concentrations of the controls in this study were almost three times lower than 
the lowest concentrations reported in the literature 1060 pg/ml (range 1060 - 18490 pg/ml) [23]. This finding 
was unanticipated as the controls were patients with degenerative spinal disease and there is evidence to support 
that serum follistatin concentrations reflect the severity of joint damage in osteoarthritis [36]. A possible expla-
nation for this difference might be that these concentrations are not directly comparable as the methodology 
used to measure them is different. However, the Bio-Rad assay used in the present study has clearly identified 
differences in the follistatin concentrations measured between the preoperative and postoperative patients as 
well as the preoperative patients and controls. 
This suggests that follistatin does indeed differ between healthy controls and tumour patients and that this 
methodology is a reliable way for measuring that. The Bio-Plex assay was proven to be a potent technique as it 
measures concentrations of multiple angiogenesis factors simultaneously from several samples within three to 
four hours. Furthermore, it is using a small quantity of sample, has low variability and high reproducibility making 
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it suitable for use in clinical practice.  
Patients affected by malignant gliomas in this study had higher pre-operative concentrations of follistatin than 
the healthy participants. Gliomas produce angiogenesis factors in response to hypoxia while promoting neoan-
giogenesis and growth [37]-[42]. Unlike the controls, the glioma patients in this present study were taking 
Dexamethasone in high dose (16 mg/day), which is widely known to down-regulate the production of VEGF, 
IL-6, follistatin and PDGF-BB [37]-[42]. Despite this, significant difference between the two groups was ob-
served. One could speculate that if the patients were not taking Dexamethasone, the measured concentrations 
would be even higher. 
To date, no studies have been reported in the literature comparing the angiogenesis factor concentrations be-
tween the patients affected by malignant glioma pre- and post-operatively. Angiogenesis factors that are related 
to the presence of the tumour would be expected to have their concentrations reduced following the tumour re-
moval. In the present study, a significant reduction of the concentrations of follistatin was observed postopera-
tively. A decrease of more than 90% of the average value (from 1133 to 86 pg/ml) for follistatin was noted. The 
effect of debulking surgery is one of the possible explanatory factors for this observation. As tumour cells con-
stitutively produce angiogenesis factors, cell removal by the surgical operation would lead to a reduced produc-
tion of these factors [30]-[35] [43]-[45]. 
Another potential cause for the drop of follistatin’s concentration in postoperative patients could be the re-
duced hypoxic drive of the tumour following the operation. Hypoxia is known to stimulate angiogenesis factor 
production by tumour cells [30]. As surgery reduces the hypoxic area of the tumour, the stimulus for such pro-
duction is also reduced.  
Age did not influence the concentration of follistatin in any of the comparisons performed as all age groups 
tested yielded the same result. Moreover no significance was found between the age group comparisons within 
each dataset. No published reports on the effect of age on the angiogenesis factor concentrations of patients with 
malignant gliomas have been found. However, a study on healthy controls reported similar findings to the con-
trols of our study in relation to age [46]. 
According to the results of this study, gender similarly to age did not influence the serum concentrations of 
follistatin tested in any of the datasets. As there are no previous reports for patients with malignant gliomas this 
finding is novel. However, studies on healthy individuals revealed that gender did not influence the follistatin 
concentrations [20]. 
This work demonstrates that follistatin is a suitable candidate biomarker for malignant gliomas. Such bio-
marker would aid clinicians with the diagnosis as well as management of patients during the course of their dis-
ease both in terms of monitoring response to treatment as well as early detection of disease recurrence. While 
angiogenesis factors such as VEGF and PDGF-BB have already been proposed for this role, their use has not 
been translated to clinical practice. This might be because they have low specificity for malignant gliomas, be-
ing present in almost all malignant and several pathological processes. These factors play a key role not only in 
the angiogenesis process that allows the tumour to grow, but also in the inflammatory processes during the 
course of benign disease. Furthermore, there is still a need to define clearly a method that will be widely vali-
dated and accepted for their measurement. 
5. Conclusion 
We are proposing follistatin as a novel biomarker for malignant gliomas. Its serum concentration differs signifi-
cantly not only between preoperative controls and preoperative glioma patients, but also between patients pre- 
and post-operatively. Furthermore, this study investigates the role of gender and age between the two operative 
stages of the glioma patients. To our knowledge, this is the first study investigating the pre- vs. post-operative 
serum concentrations of follistatin in patients with malignant gliomas. As such, it contributes to a better under-
standing of this molecule and its role in this disease. Further studies with larger group of healthy controls and 
patients are expected to strengthen the case of the use of follistatin as biomarker for malignant gliomas while it 
will allow for novel ones to be discovered. 
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